Abstract
Background: Lung adenocarcinoma (LADC) is the most common type of lung cancer and is a subtype of non-small-cell lung cancer (NSCLC). Approximately 40% of LADC patients experience brain metastases (BMs) during the course of the disease. In this study, integrated bioinformatics methods were applied to identify key genes related to brain metastasis in lung adenocarcinoma.
Methods: We derived and characterized genes differentially expressed between the primary tumour and brain metastases using tumour cells isolated from two lung cancer Patient-derived xenografts (PDX) cases (GSE 69405). Gene ontology (GO) and KEGG pathway enrichment analyses were applied, and protein-protein interaction (PPI) networks and Cytoscape software were utilized to identify key genes.
Results: Four key genes, including CKAP4 (Cytoskeleton Associated Protein 4), SERPINA1 (Serpin Family A Member 1), SDC2 (Syndecan 2) and GNG11 (G Protein Subunit Gamma 11) were identified for BM-LADC by the Venn diagram.
Conclusion: We believe these key genes may be potential biomarkers for improved prognosis and treatment of lung adenocarcinoma.
Keywords: Lung adenocarcinoma, brain metastases, single-cell RNA sequencing, bioinformatics, key genes, biomarker.
Graphical Abstract
Current Gene Therapy
Title:Single-cell RNA Sequencing Analysis Identifies Key Genes in Brain Metastasis from Lung Adenocarcinoma
Volume: 21 Issue: 4
Author(s): Zilong Zhang*, Feifei Cui, Murong Zhou, Song Wu*, Quan Zou*Bo Gao*
Affiliation:
- Institute of Fundamental and Frontier Sciences, University of Electronic Science and Technology of China, Chengdu 610054,China
- Director of Preventive Treatment of Disease Centre, Qinhuangdao Hospital of Traditional Chinese Medicine, Qinhuangdao 066000,China
- Institute of Fundamental and Frontier Sciences, University of Electronic Science and Technology of China, Chengdu 610054,China
- Second Affiliated Hospital of Harbin Medical University, Harbin Medical University, Harbin, 150080,China
Keywords: Lung adenocarcinoma, brain metastases, single-cell RNA sequencing, bioinformatics, key genes, biomarker.
Abstract:
Background: Lung adenocarcinoma (LADC) is the most common type of lung cancer and is a subtype of non-small-cell lung cancer (NSCLC). Approximately 40% of LADC patients experience brain metastases (BMs) during the course of the disease. In this study, integrated bioinformatics methods were applied to identify key genes related to brain metastasis in lung adenocarcinoma.
Methods: We derived and characterized genes differentially expressed between the primary tumour and brain metastases using tumour cells isolated from two lung cancer Patient-derived xenografts (PDX) cases (GSE 69405). Gene ontology (GO) and KEGG pathway enrichment analyses were applied, and protein-protein interaction (PPI) networks and Cytoscape software were utilized to identify key genes.
Results: Four key genes, including CKAP4 (Cytoskeleton Associated Protein 4), SERPINA1 (Serpin Family A Member 1), SDC2 (Syndecan 2) and GNG11 (G Protein Subunit Gamma 11) were identified for BM-LADC by the Venn diagram.
Conclusion: We believe these key genes may be potential biomarkers for improved prognosis and treatment of lung adenocarcinoma.
Export Options
About this article
Cite this article as:
Zhang Zilong *, Cui Feifei , Zhou Murong , Wu Song *, Zou Quan*, Gao Bo *, Single-cell RNA Sequencing Analysis Identifies Key Genes in Brain Metastasis from Lung Adenocarcinoma, Current Gene Therapy 2021; 21 (4) . https://dx.doi.org/10.2174/1566523221666210319104752
DOI https://dx.doi.org/10.2174/1566523221666210319104752 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Fungal Bioactive Compounds in Pharmaceutical Research and Development
Current Bioactive Compounds miRNAs as Modulators of Cholesterol in Breast Cancer Stem Cells: An Approach to Overcome Drug Resistance in Cancer
Current Drug Targets Targeting Apoptosis to Treat Multiple Sclerosis
Current Drug Discovery Technologies Strategies for Increasing the Solubility and Bioavailability of Anticancer Compounds: β-Lapachone and Other Naphthoquinones
Current Pharmaceutical Design Epithelial-to-Mesenchymal Transition: A Mediator of Sorafenib Resistance in Advanced Hepatocellular Carcinoma
Current Cancer Drug Targets Targeting Angiogenic Genes as a Therapeutic Approach for Hepatocellular Carcinoma
Current Gene Therapy Nanodiamonds as a New Horizon for Pharmaceutical and Biomedical Applications
Current Drug Delivery An Evolving Role of Piperazine Moieties in Drug Design and Discovery
Mini-Reviews in Medicinal Chemistry Haematopoietic Stem Cell Gene Therapy to Treat Autoimmune Disease
Current Stem Cell Research & Therapy Hesperetin Liposomes for Cancer Therapy
Current Drug Delivery Organosulfur Compounds in Cancer Chemoprevention
Mini-Reviews in Medicinal Chemistry Patented Biomarkers of Peripheral Blood for the Early Detection of Cancer
Recent Patents on Biomarkers Molecular Docking, 3D-QSAR, Fingerprint-Based 2D-QSAR, Analysis of Pyrimidine, and Analogs of ALK (Anaplastic Lymphoma Kinase) Inhibitors as an Anticancer Agent
Letters in Drug Design & Discovery ExomiRs: A Novel Strategy in Cancer Diagnosis and Therapy
Current Gene Therapy Block Copolymers for Drug Delivery Nano Systems (DDnSs)
Current Medicinal Chemistry Molecular Pharmacology and Pharmacogenomics of Artemisinin and its Derivatives in Cancer Cells
Current Drug Targets High Throughput Multiplex SNP-analysis in Chronic Obstructive Pulmonary Disease and Lung Cancer
Current Molecular Medicine Immunotherapeutic Approaches in Pancreatic Adenocarcinoma: Current Status and Future Perspectives
Current Molecular Pharmacology Pharmacogenetic and Pharmacokinetic Dose Individualization of the Taxane Chemotherapeutic Drugs Paclitaxel and Docetaxel
Current Medicinal Chemistry The Combination of Conventional Chemotherapy with New Targeted Therapy in Hematologic Malignancies: The Safety and Efficiency of Low- Dose Cytarabine Supports its Combination with New Therapeutic Agents in Early Clinical Trials
Current Cancer Therapy Reviews